The Puerto Rico Alzheimer disease initiative (PRADI): A multisource ascertainment approach

Briseida E. Feliciano-Astacio, Katrina Celis, Jairo Ramos, Farid Rajabli, Larry Deon Adams, Alejandra Rodriguez, Vanessa Rodriguez, Parker L. Bussies, Carolina Sierra, Patricia Manrique, Pedro R. Mena, Antonella Grana, Michael Prough, Kara L. Hamilton-Nelson, Nereida Feliciano, Angel Chinea, Heriberto Acosta, Jacob L McCauley, Jeffery M Vance, Gary W BeechamMargaret A Pericak-Vance, Michael Cuccaro

Research output: Contribution to journalArticle

Abstract

Introduction: Puerto Ricans, the second largest Latino group in the continental US, are underrepresented in genomic studies of Alzheimer disease (AD). To increase representation of this group in genomic studies of AD, we developed a multisource ascertainment approach to enroll AD patients, and their family members living in Puerto Rico (PR) as part of the Alzheimer's Disease Sequencing Project (ADSP), an international effort to advance broader personalized/precision medicine initiatives for AD across all populations. Methods: The Puerto Rico Alzheimer Disease Initiative (PRADI) multisource ascertainment approach was developed to recruit and enroll Puerto Rican adults aged 50 years and older for a genetic research study of AD, including individuals with cognitive decline (AD, mild cognitive impairment), their similarly, aged family members, and cognitively healthy unrelated individuals age 50 and up. Emphasizing identification and relationship building with key stakeholders, we conducted ascertainment across the island. In addition to reporting on PRADI ascertainment, we detail admixture analysis for our cohort by region, group differences in age of onset, cognitive level by region, and ascertainment source. Results: We report on 674 individuals who met standard eligibility criteria [282 AD-affected participants (42% of the sample), 115 individuals with mild cognitive impairment (MCI) (17% of the sample), and 277 cognitively healthy individuals (41% of the sample)]. There are 43 possible multiplex families (10 families with 4 or more AD-affected members and 3 families with 3 AD-affected members). Most individuals in our cohort were ascertained from the Metro, Bayamón, and Caguas health regions. Across health regions, we found differences in ancestral backgrounds, and select clinical traits. Discussion: The multisource ascertainment approach used in the PRADI study highlights the importance of enlisting a broad range of community resources and providers. Preliminary results provide important information about our cohort that will be useful as we move forward with ascertainment. We expect that results from the PRADI study will lead to a better understanding of genetic risk for AD among this population.

Original languageEnglish (US)
Article number538
JournalFrontiers in Genetics
Volume10
Issue numberJUN
DOIs
StatePublished - Jan 1 2019

Fingerprint

Puerto Rico
Alzheimer Disease
Hispanic Americans
Precision Medicine
Genetic Research
Health
Age of Onset
Islands
Population

Keywords

  • ADSP
  • Alzheimer disease
  • Ascertainment
  • Community resources
  • Diversity
  • Genetics
  • Health disparities
  • PRADI

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Genetics(clinical)

Cite this

Feliciano-Astacio, B. E., Celis, K., Ramos, J., Rajabli, F., Adams, L. D., Rodriguez, A., ... Cuccaro, M. (2019). The Puerto Rico Alzheimer disease initiative (PRADI): A multisource ascertainment approach. Frontiers in Genetics, 10(JUN), [538]. https://doi.org/10.3389/fgene.2019.00538

The Puerto Rico Alzheimer disease initiative (PRADI) : A multisource ascertainment approach. / Feliciano-Astacio, Briseida E.; Celis, Katrina; Ramos, Jairo; Rajabli, Farid; Adams, Larry Deon; Rodriguez, Alejandra; Rodriguez, Vanessa; Bussies, Parker L.; Sierra, Carolina; Manrique, Patricia; Mena, Pedro R.; Grana, Antonella; Prough, Michael; Hamilton-Nelson, Kara L.; Feliciano, Nereida; Chinea, Angel; Acosta, Heriberto; McCauley, Jacob L; Vance, Jeffery M; Beecham, Gary W; Pericak-Vance, Margaret A; Cuccaro, Michael.

In: Frontiers in Genetics, Vol. 10, No. JUN, 538, 01.01.2019.

Research output: Contribution to journalArticle

Feliciano-Astacio, BE, Celis, K, Ramos, J, Rajabli, F, Adams, LD, Rodriguez, A, Rodriguez, V, Bussies, PL, Sierra, C, Manrique, P, Mena, PR, Grana, A, Prough, M, Hamilton-Nelson, KL, Feliciano, N, Chinea, A, Acosta, H, McCauley, JL, Vance, JM, Beecham, GW, Pericak-Vance, MA & Cuccaro, M 2019, 'The Puerto Rico Alzheimer disease initiative (PRADI): A multisource ascertainment approach', Frontiers in Genetics, vol. 10, no. JUN, 538. https://doi.org/10.3389/fgene.2019.00538
Feliciano-Astacio BE, Celis K, Ramos J, Rajabli F, Adams LD, Rodriguez A et al. The Puerto Rico Alzheimer disease initiative (PRADI): A multisource ascertainment approach. Frontiers in Genetics. 2019 Jan 1;10(JUN). 538. https://doi.org/10.3389/fgene.2019.00538
Feliciano-Astacio, Briseida E. ; Celis, Katrina ; Ramos, Jairo ; Rajabli, Farid ; Adams, Larry Deon ; Rodriguez, Alejandra ; Rodriguez, Vanessa ; Bussies, Parker L. ; Sierra, Carolina ; Manrique, Patricia ; Mena, Pedro R. ; Grana, Antonella ; Prough, Michael ; Hamilton-Nelson, Kara L. ; Feliciano, Nereida ; Chinea, Angel ; Acosta, Heriberto ; McCauley, Jacob L ; Vance, Jeffery M ; Beecham, Gary W ; Pericak-Vance, Margaret A ; Cuccaro, Michael. / The Puerto Rico Alzheimer disease initiative (PRADI) : A multisource ascertainment approach. In: Frontiers in Genetics. 2019 ; Vol. 10, No. JUN.
@article{e3b6e20cd4874de187f152bb1b11b1a5,
title = "The Puerto Rico Alzheimer disease initiative (PRADI): A multisource ascertainment approach",
abstract = "Introduction: Puerto Ricans, the second largest Latino group in the continental US, are underrepresented in genomic studies of Alzheimer disease (AD). To increase representation of this group in genomic studies of AD, we developed a multisource ascertainment approach to enroll AD patients, and their family members living in Puerto Rico (PR) as part of the Alzheimer's Disease Sequencing Project (ADSP), an international effort to advance broader personalized/precision medicine initiatives for AD across all populations. Methods: The Puerto Rico Alzheimer Disease Initiative (PRADI) multisource ascertainment approach was developed to recruit and enroll Puerto Rican adults aged 50 years and older for a genetic research study of AD, including individuals with cognitive decline (AD, mild cognitive impairment), their similarly, aged family members, and cognitively healthy unrelated individuals age 50 and up. Emphasizing identification and relationship building with key stakeholders, we conducted ascertainment across the island. In addition to reporting on PRADI ascertainment, we detail admixture analysis for our cohort by region, group differences in age of onset, cognitive level by region, and ascertainment source. Results: We report on 674 individuals who met standard eligibility criteria [282 AD-affected participants (42{\%} of the sample), 115 individuals with mild cognitive impairment (MCI) (17{\%} of the sample), and 277 cognitively healthy individuals (41{\%} of the sample)]. There are 43 possible multiplex families (10 families with 4 or more AD-affected members and 3 families with 3 AD-affected members). Most individuals in our cohort were ascertained from the Metro, Bayam{\'o}n, and Caguas health regions. Across health regions, we found differences in ancestral backgrounds, and select clinical traits. Discussion: The multisource ascertainment approach used in the PRADI study highlights the importance of enlisting a broad range of community resources and providers. Preliminary results provide important information about our cohort that will be useful as we move forward with ascertainment. We expect that results from the PRADI study will lead to a better understanding of genetic risk for AD among this population.",
keywords = "ADSP, Alzheimer disease, Ascertainment, Community resources, Diversity, Genetics, Health disparities, PRADI",
author = "Feliciano-Astacio, {Briseida E.} and Katrina Celis and Jairo Ramos and Farid Rajabli and Adams, {Larry Deon} and Alejandra Rodriguez and Vanessa Rodriguez and Bussies, {Parker L.} and Carolina Sierra and Patricia Manrique and Mena, {Pedro R.} and Antonella Grana and Michael Prough and Hamilton-Nelson, {Kara L.} and Nereida Feliciano and Angel Chinea and Heriberto Acosta and McCauley, {Jacob L} and Vance, {Jeffery M} and Beecham, {Gary W} and Pericak-Vance, {Margaret A} and Michael Cuccaro",
year = "2019",
month = "1",
day = "1",
doi = "10.3389/fgene.2019.00538",
language = "English (US)",
volume = "10",
journal = "Frontiers in Genetics",
issn = "1664-8021",
publisher = "Frontiers Media S. A.",
number = "JUN",

}

TY - JOUR

T1 - The Puerto Rico Alzheimer disease initiative (PRADI)

T2 - A multisource ascertainment approach

AU - Feliciano-Astacio, Briseida E.

AU - Celis, Katrina

AU - Ramos, Jairo

AU - Rajabli, Farid

AU - Adams, Larry Deon

AU - Rodriguez, Alejandra

AU - Rodriguez, Vanessa

AU - Bussies, Parker L.

AU - Sierra, Carolina

AU - Manrique, Patricia

AU - Mena, Pedro R.

AU - Grana, Antonella

AU - Prough, Michael

AU - Hamilton-Nelson, Kara L.

AU - Feliciano, Nereida

AU - Chinea, Angel

AU - Acosta, Heriberto

AU - McCauley, Jacob L

AU - Vance, Jeffery M

AU - Beecham, Gary W

AU - Pericak-Vance, Margaret A

AU - Cuccaro, Michael

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: Puerto Ricans, the second largest Latino group in the continental US, are underrepresented in genomic studies of Alzheimer disease (AD). To increase representation of this group in genomic studies of AD, we developed a multisource ascertainment approach to enroll AD patients, and their family members living in Puerto Rico (PR) as part of the Alzheimer's Disease Sequencing Project (ADSP), an international effort to advance broader personalized/precision medicine initiatives for AD across all populations. Methods: The Puerto Rico Alzheimer Disease Initiative (PRADI) multisource ascertainment approach was developed to recruit and enroll Puerto Rican adults aged 50 years and older for a genetic research study of AD, including individuals with cognitive decline (AD, mild cognitive impairment), their similarly, aged family members, and cognitively healthy unrelated individuals age 50 and up. Emphasizing identification and relationship building with key stakeholders, we conducted ascertainment across the island. In addition to reporting on PRADI ascertainment, we detail admixture analysis for our cohort by region, group differences in age of onset, cognitive level by region, and ascertainment source. Results: We report on 674 individuals who met standard eligibility criteria [282 AD-affected participants (42% of the sample), 115 individuals with mild cognitive impairment (MCI) (17% of the sample), and 277 cognitively healthy individuals (41% of the sample)]. There are 43 possible multiplex families (10 families with 4 or more AD-affected members and 3 families with 3 AD-affected members). Most individuals in our cohort were ascertained from the Metro, Bayamón, and Caguas health regions. Across health regions, we found differences in ancestral backgrounds, and select clinical traits. Discussion: The multisource ascertainment approach used in the PRADI study highlights the importance of enlisting a broad range of community resources and providers. Preliminary results provide important information about our cohort that will be useful as we move forward with ascertainment. We expect that results from the PRADI study will lead to a better understanding of genetic risk for AD among this population.

AB - Introduction: Puerto Ricans, the second largest Latino group in the continental US, are underrepresented in genomic studies of Alzheimer disease (AD). To increase representation of this group in genomic studies of AD, we developed a multisource ascertainment approach to enroll AD patients, and their family members living in Puerto Rico (PR) as part of the Alzheimer's Disease Sequencing Project (ADSP), an international effort to advance broader personalized/precision medicine initiatives for AD across all populations. Methods: The Puerto Rico Alzheimer Disease Initiative (PRADI) multisource ascertainment approach was developed to recruit and enroll Puerto Rican adults aged 50 years and older for a genetic research study of AD, including individuals with cognitive decline (AD, mild cognitive impairment), their similarly, aged family members, and cognitively healthy unrelated individuals age 50 and up. Emphasizing identification and relationship building with key stakeholders, we conducted ascertainment across the island. In addition to reporting on PRADI ascertainment, we detail admixture analysis for our cohort by region, group differences in age of onset, cognitive level by region, and ascertainment source. Results: We report on 674 individuals who met standard eligibility criteria [282 AD-affected participants (42% of the sample), 115 individuals with mild cognitive impairment (MCI) (17% of the sample), and 277 cognitively healthy individuals (41% of the sample)]. There are 43 possible multiplex families (10 families with 4 or more AD-affected members and 3 families with 3 AD-affected members). Most individuals in our cohort were ascertained from the Metro, Bayamón, and Caguas health regions. Across health regions, we found differences in ancestral backgrounds, and select clinical traits. Discussion: The multisource ascertainment approach used in the PRADI study highlights the importance of enlisting a broad range of community resources and providers. Preliminary results provide important information about our cohort that will be useful as we move forward with ascertainment. We expect that results from the PRADI study will lead to a better understanding of genetic risk for AD among this population.

KW - ADSP

KW - Alzheimer disease

KW - Ascertainment

KW - Community resources

KW - Diversity

KW - Genetics

KW - Health disparities

KW - PRADI

UR - http://www.scopus.com/inward/record.url?scp=85068966270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068966270&partnerID=8YFLogxK

U2 - 10.3389/fgene.2019.00538

DO - 10.3389/fgene.2019.00538

M3 - Article

AN - SCOPUS:85068966270

VL - 10

JO - Frontiers in Genetics

JF - Frontiers in Genetics

SN - 1664-8021

IS - JUN

M1 - 538

ER -